Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04975958` - Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors	Phase 1
Recruiting	`NCT05919537` - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation	Phase 1
Active, not recruiting	`NCT04383210` - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Phase 2
Recruiting	`NCT05378425` - A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab	Phase 1
Recruiting	`NCT04260802` - A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers	Phase 1/Phase 2
Not yet recruiting	`NCT05028478` - A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT04250948` - Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer	Phase 2
Recruiting	`NCT06184035` - A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer	Phase 1/Phase 2
Completed	`NCT04914117` - A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours	Phase 1
Recruiting	`NCT04614740` - The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04770688` - Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib	Phase 1/Phase 2
Not yet recruiting	`NCT06415487` - ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)	Phase 1
Not yet recruiting	`NCT06349408` - IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06028724` - A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
Recruiting	`NCT05732831` - Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03284502` - HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT01390818` - Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05919264` - FOG-001 in Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04319757` - ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors	Phase 1
Recruiting	`NCT03881488` - Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies	Phase 1

NCT number	NCT04084366
Study type	Interventional
Source	OBI Pharma, Inc
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	December 10, 2019
Completion date	October 27, 2023

Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms